Analysts Set Expectations for ImageneBio FY2025 Earnings

ImageneBio, Inc. (NASDAQ:IMA) – Stock analysts at William Blair issued their FY2025 earnings estimates for ImageneBio in a research report issued on Wednesday, November 12th. William Blair analyst M. Phipps forecasts that the company will post earnings of ($9.34) per share for the year. The consensus estimate for ImageneBio’s current full-year earnings is ($0.91) per share. William Blair also issued estimates for ImageneBio’s Q4 2025 earnings at ($1.15) EPS, Q1 2026 earnings at ($1.19) EPS, Q2 2026 earnings at ($1.07) EPS, Q3 2026 earnings at ($1.06) EPS, Q4 2026 earnings at ($1.07) EPS, FY2026 earnings at ($4.38) EPS, FY2027 earnings at ($4.12) EPS, FY2028 earnings at ($4.16) EPS and FY2029 earnings at ($3.52) EPS.

ImageneBio (NASDAQ:IMA) last issued its earnings results on Wednesday, November 12th. The company reported ($2.91) earnings per share for the quarter, missing the consensus estimate of ($1.47) by ($1.44).

A number of other research firms have also issued reports on IMA. Wedbush cut their price target on shares of ImageneBio from $25.00 to $23.00 and set a “neutral” rating on the stock in a report on Friday, July 25th. Weiss Ratings initiated coverage on shares of ImageneBio in a report on Wednesday, October 22nd. They issued a “sell (e-)” rating on the stock. Leerink Partners began coverage on shares of ImageneBio in a research note on Friday, October 24th. They issued an “outperform” rating and a $30.00 target price for the company. Zacks Research cut shares of ImageneBio from a “strong-buy” rating to a “hold” rating in a research note on Monday, September 29th. Finally, Leerink Partnrs raised shares of ImageneBio to a “strong-buy” rating in a research note on Friday, October 24th. One analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, ImageneBio has a consensus rating of “Hold” and a consensus price target of $26.50.

ImageneBio Stock Performance

Shares of IMA stock opened at $8.16 on Monday. The business’s fifty day moving average is $8.26 and its 200-day moving average is $12.66. ImageneBio has a 1 year low of $7.24 and a 1 year high of $23.28. The stock has a market cap of $32.72 million, a PE ratio of -1.01 and a beta of 0.42.

Hedge Funds Weigh In On ImageneBio

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Deep Track Capital LP acquired a new stake in shares of ImageneBio in the 3rd quarter valued at $7,160,000. Blue Owl Capital Holdings LP acquired a new position in ImageneBio during the 3rd quarter worth approximately $4,409,000. Atlas Venture Life Science Advisors LLC bought a new position in ImageneBio in the 3rd quarter valued at approximately $3,079,000. Aldebaran Capital LLC bought a new position in ImageneBio in the 1st quarter valued at approximately $317,000. Finally, Vanguard Group Inc. acquired a new stake in ImageneBio in the third quarter valued at approximately $1,902,000. 75.00% of the stock is owned by institutional investors and hedge funds.

ImageneBio Company Profile

ImageneBio, Inc, a clinical-stage biotechnology company, develops therapeutics for immunological and inflammatory diseases. Its lead product includes IMG-007, a non-depleting anti-OX40 mAb that has completed Phase 2a clinical trials for the treatment of atopic dermatitis and alopecia areata. The company was formerly known as Ikena Oncology, Inc and changed its name to ImageneBio, Inc in July 2025.